Curative Biotechnology IncOTC Pink - Current Information:CUBT
- LAST PRICE0.0193
- TODAY'S CHANGE (%)0.0006 (3.2086%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0176 / 0.0187
- Day Range
- 52 Week Range
- Volume154,077
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CUBT |
|---|---|---|
| 01:15 ET | 1000 | 0.0176 |
| 01:26 ET | 5000 | 0.0187 |
| 01:35 ET | 31377 | 0.0187 |
| 01:37 ET | 2500 | 0.0193 |
| 01:39 ET | 10000 | 0.01875 |
| 01:42 ET | 10000 | 0.01875 |
| 02:08 ET | 34000 | 0.0187 |
| 02:09 ET | 2500 | 0.0193 |
| 03:07 ET | 35000 | 0.0193 |
| 03:32 ET | 20000 | 0.0187 |
| 03:50 ET | 200 | 0.0182 |
| 03:54 ET | 2500 | 0.0193 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Curative Biotechnology Inc | 10.7M | -1.8x | --- |
Neximmune Inc | 10.8M | -0.2x | --- |
Context Therapeutics Inc | 10.5M | -0.7x | --- |
ENDRA Life Sciences Inc | 10.5M | -0.7x | --- |
Galmed Pharmaceuticals Ltd | 10.8M | -0.5x | --- |
Innovation Pharmaceuticals Inc | 10.9M | -2.1x | --- |
Company Information
Curative Biotechnology, Inc. (Curative Biotech) is a development-stage biomedical company focused on treatments for rare diseases and conditions. The Company is focused on identifying, acquiring and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. The Company has programs in three therapeutic areas: infectious disease, neuro oncology and degenerative eye disease. The Company’s pipeline products include IMT504, CURB906 and Metformin Reformulation. IMT504 is an immune therapy to treat rabies and an adjuvant for vaccines. CURB906 is a humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor cancer site to kill the tumor by inhibiting tumor growth and migration of the tumor. Metformin Reformulation is focused in treatment of intermediate and late-stage age-related macular degeneration (AMD) disease.
Contact Information
- Headquarters
- 1825 Nw Corporate Blvd, Suite 110BOCA RATON, FL, United States 33431
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board, President
- Paul Michaels
- Chief Executive Officer, Chief Financial Officer, General Counsel
- Richard Garr
- Director
- Michael Fish
- Director, Chief Strategy Officer
- Barry Ginsberg
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $10.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 571.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.01 |
Book Value | $0.00 |
P/E Ratio | -1.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
